Vulnerable plaque PCI after PREVENT

PCR Perspectives

Summary

This interview with Michael Haude and Thomas Cuisset explores findings from the PREVENT trial, which included over 1,600 patients with vulnerable, physiologically non-significant plaques identified by IVUS.

Patients were randomised to optimal medical therapy (OMT) alone or OMT plus preventive PCI. While the composite endpoint favoured the PCI group, the benefit was driven solely by a reduction in target lesion revascularisation—with no difference in death or myocardial infarction.

Should these plaques be systematically treated? Watch the discussion!

This interview was filmed at EuroPCR 2025: see more videos here.

Also available in podcast format:

This podcast is also available on Spotify and Apple Podcasts